Has It Been Found? What Does It Reveal About Pfizer's Social Media Implementation Plan?. Ray Kerins (@raykerins), Vice President of Worldwide Communications at Pfizer, talks about Pfizer's 'groundbreaking internal Social Media Playbook' but won't show it to us. What can be in the playbook? How many people does Pfizer dedicate to social media? This article discusses those questions and offers a peek into a playbook contender.
If you're thinking of developing a mobile application (app) for patients or physicians, you need to consider the myriad platforms -- hardware plus software combinations -- that are out there and determine which platform is best suited for your intended audience. Your choice of platform will impact your app's performance, maintenance, and security, which in turn will make or break the success of the app.
Pharma companies need to drive maximum value out of products and they can't do that with a 'one-size-fits-all' cookie-cutter approach to deploying field forces. Brand managers will look to outsourced providers to take advantage of the expertise these providers can bring to the table. This article is a summary of an interview of Nancy Lurker, CEO of PDI, Inc., which provides promotional outsourced services to healthcare companies.
Why do pharma companies bother developing drugs for for a disorder affecting fewer than 200,000 people? Willie Sutton's ghost may have the answer.
Welcome to Volume 10, Issue #1 (JANUARY 12, 2011) of Pharma Marketing News.
This article focuses on Adobe Connect for eDetailing, a specific collaboration between Adobe and ConnectSolutions, a leading provider of private cloud deployments of web conferencing and collaboration solutions.
Let's look 'under the hoods' of two pharma-sponsored mobile apps and compare disclaimers. We'll compare Janssen's PASI calculator, which has an update disclaimer, with the new AFib Educator 2.0 app developed by Sanofi-Aventis.
Talk about having your cake and eating it too! Commercial funding of continuing medical education (CME) and the potential for bias appear to concern many physicians, yet only a TINY MINORITY (7%) are willing to pay registration fees to eliminate or offset commercial funding sources, according to a report in the May 9, 2011, issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Welcome to Volume 10, Issue #13 (23 AUGUST 2011) of Pharma Marketing News.
HepC.tv is featuring the video 'Man-on-the-Street: New Yorkers' Reactions to the Big Yellow C.' Is it effective? How do we know?